Lazard Asset Management LLC lifted its stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Rating) by 80.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,330 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,926 shares during the quarter. Lazard Asset Management LLC’s holdings in Eagle Pharmaceuticals were worth $192,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in EGRX. Goldman Sachs Group Inc. increased its holdings in shares of Eagle Pharmaceuticals by 65.3% in the first quarter. Goldman Sachs Group Inc. now owns 178,306 shares of the specialty pharmaceutical company’s stock valued at $8,825,000 after purchasing an additional 70,438 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Eagle Pharmaceuticals by 31.9% in the first quarter. Acadian Asset Management LLC now owns 139,695 shares of the specialty pharmaceutical company’s stock valued at $6,908,000 after purchasing an additional 33,816 shares during the last quarter. Ergoteles LLC acquired a new stake in shares of Eagle Pharmaceuticals in the first quarter valued at approximately $1,164,000. Vanguard Group Inc. increased its holdings in shares of Eagle Pharmaceuticals by 2.7% in the first quarter. Vanguard Group Inc. now owns 780,851 shares of the specialty pharmaceutical company’s stock valued at $38,644,000 after purchasing an additional 20,383 shares during the last quarter. Finally, Royce & Associates LP increased its holdings in shares of Eagle Pharmaceuticals by 96.4% in the first quarter. Royce & Associates LP now owns 36,622 shares of the specialty pharmaceutical company’s stock valued at $1,812,000 after purchasing an additional 17,978 shares during the last quarter. Institutional investors and hedge funds own 88.49% of the company’s stock.
Insider Buying and Selling
In related news, Director Richard A. Edlin sold 6,800 shares of the stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $30.99, for a total value of $210,732.00. Following the completion of the transaction, the director now directly owns 22,600 shares in the company, valued at $700,374. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 28.20% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Eagle Pharmaceuticals Trading Up 2.6 %
Shares of Eagle Pharmaceuticals stock opened at $37.56 on Monday. The firm has a market capitalization of $488.88 million, a price-to-earnings ratio of 19.56 and a beta of 0.80. Eagle Pharmaceuticals, Inc. has a fifty-two week low of $24.35 and a fifty-two week high of $56.43. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.99 and a current ratio of 1.52. The stock has a 50 day moving average of $30.56 and a 200 day moving average of $37.75.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
- Get a free copy of the StockNews.com research report on Eagle Pharmaceuticals (EGRX)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.